Conference Coverage
Conference Coverage
VIDEO: Ibrutinib PFS is nearly 3 years in MCL patients who had one prior therapy
ATLANTA – Dr. Simon Rule discusses the implications of the study and how ibrutinib stacks up against other therapies for MCL.
Conference Coverage
VIDEO: Venetoclax/rituximab prolongs PFS in relapsed/refractory CLL
ATLANTA – Dr. John Seymour discussed results from a study comparing bendamustine/rituximab with venetoclax/rituximab in relapsed/refractory CLL...
Conference Coverage
VIDEO: CAR T cell axi-cel drives B-cell lymphomas into remission
Dr. Sattva S. Neelapu describes efforts to manage adverse events common to CAR T-cell therapies, notably cytokine release syndrome.
Conference Coverage
CLL drug combinations induce MRD negativity
ATLANTA – The potential of two- and three-drug combinations to induce MRD-negative responses in CLL patients was demonstrated in multiple studies...
Conference Coverage
CLARITY: Ibrutinib/venetoclax combo results look promising for relapsed/refractory CLL
ATLANTA – Ibrutinib/venetoclax is well tolerated and shows promise for relapsed/refractory CLL, according to early CLARITY feasibility trial...
Conference Coverage
Updated ZUMA-1 data show durable CAR-T responses in B-cell lymphomas
ATLANTA – Updated results in 108 patients with refractory B cell lymphomas showed an ORR of 82%, including 58% complete responses, after a median...
Conference Coverage
Avapritinib yields high response rate in patients with systemic mastocytosis
ATLANTA – Avapritinib was well tolerated in the phase 1 trial, and demonstrated encouraging preliminary activity.
Conference Coverage
ASCT or novel therapies in early relapsing follicular lymphoma?
NEW YORK – Should autologous stem cell transplantation or novel therapies be the next step when a patient with follicular lymphoma experiences...
Conference Coverage
Marginal zone lymphoma treatment studies to be presented at ASH
Several studies will focus on combination treatment approaches in MZL.
Conference Coverage
CAR T-cells gain ground against hematologic cancers
New data from the ZUMA-1 and JULIET studies will be presented at ASH 2017.